Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors
Researchers mapped how tumor tissue physically blocks antibody drugs from reaching cancer cells, revealing specific barriers worth attacking alongside existing therapies.
This Nat Biotechnol study introduces SSP — integrating fluorescently labeled antibody imaging with high-plex spatial proteomics — and applies it to HNSCC and PDAC human tumor samples from phase 1 trials, revealing conserved stromal barriers that limit panitumumab delivery at the single-cell level. The conserved nature of these barriers (periostin-ECM, FAP+ CAFs) across tumor types provides a mechanistic rationale for combining antibody therapies with stromal targeting strategies.
What the study was
- Study design
- Translational study using human tumor tissue from phase 1 clinical trials
- Population
- Head and neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma (PDAC) patients from phase 1 panitumumab-IRDye800 trials
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Nat Biotechnol
Why it surfaced
Nat Biotechnol publication. Genuinely novel methodology (SSP) applied to human phase 1 trial samples — provides first single-cell drug delivery mapping in vivo. Identifies conserved, potentially actionable stromal barriers. Stanford/Nolan lab provenance (Akoya Biosciences relationship noted but methodology is reagent-independent).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.